Beijing–(BUSINESS WIRE)–(BUSINESS WIRE)–Kexing Holding Biotechnology Co., Ltd. (“Kexing” or the “Company”) (NASDAQ: SVA), a leading supplier of biopharmaceutical products in China, announced that the Government of the Hong Kong Special Administrative Region of the People’s Republic of China The Department of Health has approved the company’s new crown vaccine “CoronaVac” for children from 6 months to 3 years old based on local clinical trials and research related to vaccination of children and adolescents.
The vaccination schedule for this age group is the same as for older children. Children 6 months to under 3 years of age receive three doses, the first two doses are 28 days apart, and the third dose and the second dose are at least 3 months apart. Immunosuppressed children can also be vaccinated.
The Scientific Committee on Vaccine-Preventable Diseases and the Scientific Committee on Emerging and Infectious Diseases of Animals under the Centre for Health Protection of the Department of Health, together with the Chief Executive’s Expert Advisory Panel, released on 1 August 2022 on vaccination against Covid-19 in children aged 6 months or above in Hong Kong tentative consensus recommendations.
Sinovac has launched a Phase III clinical study of the new crown vaccine Kellev in children and adolescents aged 6 months to 17 years from 2021. Preliminary results show that the vaccine has good safety and immunogenicity. No serious adverse reactions were reported in children aged 6 months to 35 months in the 6 months following two doses of the vaccine.
From February 15, 2022, Clarion has received emergency authorization in Hong Kong for minors and adults over the age of 3. As of August 2022, Clarify has been approved for minors in 14 countries in Latin America, including Chile, Colombia, Ecuador, Brazil, and other countries in the Asia and Africa region.
Sinovac Holding Biotechnology Co., Ltd. (SINOVAC) is a biopharmaceutical company headquartered in China, focusing on the research and development, production and sales of vaccines to prevent human infectious diseases.
Sinovac’s product portfolio includes treatments for novel coronavirus, enterovirus 71 (EV71) infection hand, foot and mouth disease (HFMD), hepatitis A and B, seasonal influenza, pneumococcal disease, H5N1 pandemic influenza (bird flu), H1N1 Vaccines for influenza (swine flu), chickenpox, mumps and polio.
Novel coronavirus vaccine CoronaVac®) is approved for vaccination in more than 60 countries and regions around the world. Healive Hepatitis A Vaccine®) passed the WHO prequalification requirements in 2017. Enterovirus 71 vaccine Inlive®) is an innovative vaccine commercialized in China in 2016. In 2022, Sinovac’s Sabin strain inactivated polio vaccine (sIPV) was prequalified by the World Health Organization.
Kexing’s Panflu.1 (Panflu.1®) was the first approved H1N1 influenza vaccine. The vaccine underpins the Chinese government’s vaccination campaign and stockpiling program. The company is also an H5N1 pandemic influenza vaccine Panflu®), the only supplier of vaccines for the Chinese government’s stockpile program.
Sinovac is constantly committed to the research and development of new vaccines and continues to explore global market opportunities. Currently, there are more combination vaccine products in its pipeline. Sinovac plans to conduct wider and deeper trade and cooperation with more countries, enterprises and industry organizations.
For more information, please visit the company’s website: www.sinovac.com.
Disclaimer: The original version of this announcement is the official authorized version. The translation is for convenience only. Please refer to the original text. The original version is the only legally binding version.